Other
Phase II Clinical Study
0
Pipeline Programs↗
22
Active Trials↗
5
Companies Involved↗
Phase II Clinical Study is an early-stage landscape with 0 programs across 5 companies. The most active players are Shanghai Henlius Biotech, Suzhou Suncadia Biopharmaceuticals Co., Ltd., GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
30
clinical trials
Not yet recruiting10 · 33%
Recruiting10 · 33%
Completed5 · 17%
Unknown status3 · 10%
Active, not recruiting1 · 3%
Enrolling by invitation1 · 3%
Clinical Trials
Trial Activity
30 trials
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06863506·78 enrolled
Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor
Recruiting·—·Phase 2·NCT06540937·50 enrolled
A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
Not yet recruiting·—·Phase 2·NCT07099794·90 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)